1 Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University , Utrecht, The Netherlands .
2 Schutjens de Bruin , Tilburg, The Netherlands .
J Palliat Med. 2018 Jul;21(7):963-969. doi: 10.1089/jpm.2017.0595. Epub 2018 Apr 6.
In 2011-2013, >95% of the global opioid analgesics consumption occurred in three regions, accounting for 15% of the world population. Despite abundant literature on barriers to access, little is known on the correlation between actual access to opioid analgesics and barriers to access, including legal and regulatory barriers.
This study aimed to evaluate the correlation between access to strong opioid analgesics and barriers to access in national legislation and regulations in 11 central and eastern European countries that participated in the Access to Opioid Medication in Europe (ATOME) project.
Two variables were contrasted to assess their correlation: the country level of access to strong opioid analgesics indicated by the Adequacy of Consumption Measure (ACM) and the number of potential legal and regulatory barriers identified by an external review of legislation and regulations.
A linear correlation was evaluated using a squared linear correlation coefficient.
Evaluation of the correlation between the ACM and the number of potential barriers produces an R value of 0.023 and a correlation plot trend line gradient of -0.075, indicating no correlation between access to strong opioid analgesics and the number of potential barriers in national legislation and regulations in the countries studied.
No correlation was found, which indicates that other factors besides potential legal and regulatory barriers play a critical role in withholding prescribers and patients essential pain medication in the studied countries. More research is needed toward better understanding of the complex interplay of factors that determine access to strong opioid analgesics.
2011 年至 2013 年，全球超过 95%的阿片类镇痛药消费发生在三个地区，占世界人口的 15%。尽管有大量关于获取障碍的文献，但对于实际获取阿片类镇痛药与获取障碍之间的相关性，包括法律和监管障碍，知之甚少。
本研究旨在评估 11 个参加欧洲阿片类药物获取（ATOME）项目的中东欧国家的国家立法和法规中，强阿片类镇痛药的获取与获取障碍之间的相关性。
对比了两个变量以评估它们的相关性：国家强阿片类镇痛药获取水平，由消耗适宜性衡量指标（ACM）表示，以及通过立法和法规外部审查确定的潜在法律和监管障碍数量。
使用平方线性相关系数评估线性相关性。
评估 ACM 与潜在障碍数量之间的相关性产生的 R 值为 0.023，相关图趋势线梯度为-0.075，表明在研究国家的国家立法和法规中，强阿片类镇痛药的获取与潜在障碍的数量之间没有相关性。
未发现相关性，这表明在研究国家中，除了潜在的法律和监管障碍之外，还有其他因素在限制医生和患者获得基本的疼痛药物。需要进一步研究以更好地理解决定强阿片类镇痛药获取的复杂因素相互作用。
